Landauer Inc

Landauer — FY2011 Earnings Presentation

14 slides from Landauer's earnings presentation, Dec 7, 2011

  1. Slide 1: Fiscal 2011 Fourth Quarter and Year End Results

    LANDAUER, INC. Fiscal 2011 Fourth Quarter and Year End Results December 6 th , 2011

  2. Slide 2: Safe Harbor Statement

    This presentation may contain forward-looking statements, including statements about the outlook and prospects for Company and industry growth, as well as statements about the Company’s future financial and operating performance. Some of the information shared here constitutes forward-looking statem

  3. Slide 3: Recent Financial Performance: Fiscal 2011 Highlights

    Recent Financial Performance 3 Fiscal 2011 Highlights  Revenue grew 5.3 percent to $120.5 million.  Gross profit grew 4.4 percent to $72.9 million on increased revenue and mix.  Operating income increased $0.3 million, to $34.9 million  Net income rose 3.6 percent to $24.5 million, or $2.58 per

  4. Slide 4: Landauer Strategy Overview

    Value Creation Deliver Upside Growth 1.Optimize Core 2.Competitive Growth 3. Strategic Expansion Strategic Priorities Landauer Strategy Overview Strategic ExpansionOptimize the Core Competitive Growth  New Management in 2006  Restructure: Cost  IT/ERP system upgrades  OSL / InLight –new internat

  5. Slide 5: Radiation Safety Continuum

    Radiation Safety Continuum Existing Services with Penetration Opportunities* Complementary Adjacent Products / Services _____________________ (1) Average Revenue per Facility greater than $400K. Along the Radiation Safety Continuum 5 IZI Medical Physics Core Business Greater than $1.1 Billion US Mar

  6. Slide 6: Competitive Growth: Penetration with US Military

    6 Competitive Growth Penetration with US Military  Expanding application of next generation technology to pursue global military and first responder radiation monitoring markets  The U.S. military issued orders totaling $14.5 million to upgrade the Army’s tactical dosimetry capabilities, which wil

  7. Slide 7: Emergency Response Mutual Aid / Synchronization

    Emergency Response Mutual Aid / Synchronization 7

  8. Slide 8: Strategic Expansion - Medical Physics

    Strategic Expansion –Medical Physics Market Dynamics / OpportunityHighlights x $1.0 billion domestic market (largest player in market –by 3x) x Approximately 6,000 hospitals perform 37 million nuclear medicine procedures per year (10 million in U.S.) x Radiopharmaceutical utilization growing at over

  9. Slide 9: Strategic Expansion - IZI Medical Products: Acquisition Overview

    Strategic Expansion –IZI Medical Products  Acquired 100% of the outstanding equity of IZI Medical Products for approximately $93 million cash, subject to certain customary purchase price adjustments  The acquisition is expected to be $0.12 to $0.16 accretive to EPS (earnings per share) in fiscal 2

  10. Slide 10: Strategic Expansion - IZI Medical Products: Transaction Rationale

    10 Strategic Expansion –IZI Medical Products  IZI represents a logical extension of Landauer’s radiation safety continuum ― Significant channel leverage for expanded product offering ― Enhances complementary product / service offerings ― Accretive both financially and operationally ― Broadens addre

  11. Slide 11: Optimize the Core: Systems Initiative Update

    11 Optimize the Core Systems Initiative Update  We are on schedule to support “Go-Live”of the final phase of the project in fiscal 2012  Substantial expense will be incurred in fiscal 2012 to support the successful launch of the system – $4.4 million ($2.9 million net of tax) of non-recurring expe

  12. Slide 12: LDR Dividend Policy

    12 LDR Dividend Policy  We are committed to maintaining a competitive dividend and will continue to return cash to shareholders in this manner going forward  Board of Directors declared a regular quarterly cash dividend of$0.55 per share for the first quarter of fiscal 2012 – This represents an an

  13. Slide 13: Guidance: Fiscal 2012 Outlook

    Guidance 13 Fiscal 2012 Outlook  Expected Revenue $150 to $157 million, which includes 10 months of contributions from the recent IZI Medical Products acquisition. Also reflects: – $4.4 million ($2.9 million net of tax) of non-recurring expense spending to support the successful completion of the C

  14. Slide 14: Questions?

    Questions? Fiscal 2011 Fourth Quarter and Year End Results December 6 th , 2011

Landauer — FY2011 Earnings Presentation on 6ix